CStone and Pfizer announce China approval of sugemalimab in lung cancer

 

• The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy
• Sugemalimab became the first anti-PD-1/PD-L1 monoclonal antibody approved for stage III NSCLC following concurrent or sequential chemoradiotherapy. It's also the only anti-PD-(L)1 monoclonal antibody approved for both stage III and stage IV NSCLC
• This is the eighth approved new drug application (NDA) for CStone

https://www.biospace.com/article/releases/cstone-and-pfizer-announce-nmpa-approval-of-sugemalimab-in-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer/